Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG003 with or without pucotenlimab in recurrent or metastatic salivary gland cancer
ChiCTR2600118473Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Feb 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of becotatug vedotin in salivary gland cancer (SGC), Mucoepidermoid carcinoma (MEC), Salivary gland adenocarcinoma (SGAC) and 1 more (4 cohorts), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Objective response rate. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
becotatug vedotin
03
Conditions
salivary gland cancer (SGC)Mucoepidermoid carcinoma (MEC)Salivary gland adenocarcinoma (SGAC)acinic cell carcinoma (ACC)
Beyond the preview
Go deeper on ChiCTR2600118473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118473.